NCT05540860Phase 2Active not recruiting

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)

Study sponsor: Edgewise Therapeutics, Inc. · EWTX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-01Estimated

Enrollment · participants76Actual

Source updated2025-11-12Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-11-12 · 1 field changed

Primary completion date changed

− Before

~~Feb 2026~~

+ After

Jan 2027

Check registry source

Study details

Conditions studied

Duchenne Muscular Dystrophy

Treatments or interventions studied

Sevasemten Dose 1Drug
Sevasemten Dose 2Drug
Sevasemten Dose 3Drug
Sevasemten Dose 4Drug
Sevasemten Dose 5Drug
PlaceboDrug

Primary outcomes · main study measures

measure: Number of adverse events during treatment with sevasemten or placebo; description: All participants; timeFrame: 48 months; measure: Severity of adverse events during treatment with sevasemten or placebo; description: All participants; timeFrame: 48 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history